FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages

  Baudy, Andreas R ^a   Dogan, Taner ^a   Flores Mercado, Judith E ^a   Hoeflich, Klaus P ^a   Su, Fei ^b   van Bruggen, Nicholas ^a   Williams, Simon Peter ^a  

^a GENENTECH INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Drug resistance; GDC 0973; Melanoma; Positron emission tomography; Vemurafenib

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GDC 0973; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE ISOENZYME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT; WILD TYPE;

EID: 84875912189     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-22     Document Type: Article

References (40)

1. Bastiaannet E, Hoekstra HJ, Hoekstra OS: Melanoma. Methods Mol Biol. 2011, 727:123-139.
2. Gogas HJ, Kirkwood JM, Sondak VK: Chemotherapy for metastatic melanoma: time for a change? Cancer 2007, 109:455-464.
3. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
4. Ibrahim N, Haluska FG: Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol. 2009, 4:551-579.
5. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R: BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011, 6:e25806.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
7. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GFL, McArthur GA, Schadendorf D, Garraway LA: RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2011, 30:316-321.
8. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam M, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S: RAF inhibitors prime wildtype RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
9. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009, 106:20411-20416.
10. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G: Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2011, 72:969-978.
11. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
12. Aplin AE, Kaplan FM, Shao Y: Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 2011, 131:1817-1820.
13. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215.
14. Lemech C, Infante J, Arkenau HT: The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol. 2012, 4:61-73.
15. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2011, 72:210-219.
16. Almuhaideb A, Papathanasiou N, Bomanji J: 18 F-FDG PET/CT imaging in oncology. Ann Saudi Med. 2011, 31:3-13.
17. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T: Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 2008, 249:836-844.
18. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11:2785-27808.
19. Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, Wobbes T: Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003, 29:662-664.
20. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, Sørensen SS, Drzewiecki KT, Højgaard L, Friberg L: Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000, 27:70-75.
21. Morgan B: Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol. 2011, 8:517-527.
22. Li Q, Leahy RM: Statistical modeling and reconstruction of randoms precorrected PET data. IEEE Trans Med Imaging 2006, 25:1565-1572.
23. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985, 5:584-590.
24. Green LA, Gambhir SS, Srinivasan A, Banerjee PK, Hoh CK, Cherry SR, Sharfstein S, Barrio JR, Herschman HR, Phelps ME: Noninvasive methods for quantitating blood timeactivity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J Nucl Med 1998, 39:729-734.
25. Dean CB, Nielsen JD: Generalized linear mixed models: a review and some extensions. Lifetime Data Anal. 2007, 13:497-512.
26. Williams SP, Flores-Mercado JE, Port RE, Bengtsson T: Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transport. Eur J Nucl Med Mol Imaging 2012, 2:6.
27. Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M: Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009, 69:3042-3051.
28. Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G: Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res 2008, 27:34.
29. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
30. Kostakoglu L, Agress H Jr, Goldsmith SJ: Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics 2003, 23:315-340.
31. Nissan MH, Solit DB: The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep. 2011, 13:479-487.
32. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired BRAF inhibitor resistance. Nat Commun. 2012, 3:724.
33. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
34. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010, 8:39.
35. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R, Abel ED, Anderson SM: Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One 2011, 6:e23205.
36. Macheda ML, Rogers S, Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202:654-662.
37. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N: Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
38. Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA: Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010, 2010:1-14.
39. Doe MR, Ascano JM, Kaur M, Cole MD: Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res 2012, 72:949-957.
40. Behrooz A, Ismail-Beigi F: Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci. 1999, 14:105-110.